SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 235 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,457,819 | -30.8% | 52,877 | -24.5% | 0.00% | – |
| Q2 2023 | $2,106,394 | -9.2% | 70,073 | +9.4% | 0.00% | – |
| Q1 2023 | $2,320,024 | +278.1% | 64,036 | +272.3% | 0.00% | – |
| Q4 2022 | $613,524 | -68.2% | 17,200 | -69.8% | 0.00% | – |
| Q3 2022 | $1,928,000 | +46.3% | 56,943 | +24.9% | 0.00% | – |
| Q2 2022 | $1,318,000 | -34.8% | 45,600 | -27.0% | 0.00% | – |
| Q1 2022 | $2,020,000 | -62.0% | 62,500 | -65.7% | 0.00% | – |
| Q4 2021 | $5,320,000 | +224.4% | 182,440 | +196.8% | 0.00% | – |
| Q3 2021 | $1,640,000 | +20.9% | 61,468 | +39.7% | 0.00% | – |
| Q2 2021 | $1,356,000 | -39.9% | 44,001 | -49.0% | 0.00% | – |
| Q1 2021 | $2,257,000 | -39.9% | 86,208 | -42.3% | 0.00% | – |
| Q4 2020 | $3,756,000 | +225.8% | 149,356 | +169.9% | 0.00% | – |
| Q3 2020 | $1,153,000 | +24.4% | 55,339 | +41.7% | 0.00% | – |
| Q2 2020 | $927,000 | +34.2% | 39,054 | +1.7% | 0.00% | – |
| Q1 2020 | $691,000 | -82.9% | 38,383 | -77.5% | 0.00% | -100.0% |
| Q4 2019 | $4,045,000 | -48.3% | 170,530 | -40.1% | 0.00% | -66.7% |
| Q3 2019 | $7,824,000 | -81.2% | 284,687 | -77.4% | 0.00% | -40.0% |
| Q2 2019 | $41,637,000 | +228.1% | 1,258,281 | +247.5% | 0.01% | 0.0% |
| Q1 2019 | $12,689,000 | +1.8% | 362,145 | -3.5% | 0.01% | -16.7% |
| Q4 2018 | $12,464,000 | -1.8% | 375,171 | +48.9% | 0.01% | +50.0% |
| Q3 2018 | $12,688,000 | +9.2% | 251,979 | +29.8% | 0.00% | +33.3% |
| Q2 2018 | $11,621,000 | +39.9% | 194,160 | +7.0% | 0.00% | 0.0% |
| Q1 2018 | $8,308,000 | +9.0% | 181,400 | -5.2% | 0.00% | 0.0% |
| Q4 2017 | $7,623,000 | -38.2% | 191,291 | -37.9% | 0.00% | -40.0% |
| Q3 2017 | $12,325,000 | +21.6% | 308,137 | +31.0% | 0.01% | +25.0% |
| Q2 2017 | $10,135,000 | +75.5% | 235,151 | +27.4% | 0.00% | 0.0% |
| Q1 2017 | $5,776,000 | -0.4% | 184,565 | -19.7% | 0.00% | +100.0% |
| Q4 2016 | $5,800,000 | +117.4% | 229,734 | +113.0% | 0.00% | +100.0% |
| Q3 2016 | $2,668,000 | -31.6% | 107,865 | -43.7% | 0.00% | -50.0% |
| Q2 2016 | $3,900,000 | +22.0% | 191,465 | -8.7% | 0.00% | +100.0% |
| Q1 2016 | $3,197,000 | +21.0% | 209,669 | +6.6% | 0.00% | -50.0% |
| Q4 2015 | $2,642,000 | -9.6% | 196,606 | -5.6% | 0.00% | 0.0% |
| Q3 2015 | $2,923,000 | -12.7% | 208,310 | +5.6% | 0.00% | +100.0% |
| Q2 2015 | $3,349,000 | +42.1% | 197,261 | +1.2% | 0.00% | 0.0% |
| Q1 2015 | $2,357,000 | +4.9% | 194,926 | -28.0% | 0.00% | – |
| Q4 2014 | $2,246,000 | +27.8% | 270,635 | +33.8% | 0.00% | – |
| Q3 2014 | $1,758,000 | -35.7% | 202,300 | -19.0% | 0.00% | -100.0% |
| Q2 2014 | $2,734,000 | +14.8% | 249,653 | -6.3% | 0.00% | 0.0% |
| Q1 2014 | $2,382,000 | -55.0% | 266,405 | -62.1% | 0.00% | -50.0% |
| Q4 2013 | $5,297,000 | -27.8% | 702,495 | -29.8% | 0.00% | -50.0% |
| Q3 2013 | $7,333,000 | +276.2% | 1,000,394 | +230.0% | 0.00% | +300.0% |
| Q2 2013 | $1,949,000 | – | 303,107 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HealthInvest Partners AB | 335,000 | $8,934,000 | 13.38% |
| ASHFORD CAPITAL MANAGEMENT INC | 1,016,665 | $27,114,000 | 2.46% |
| Bruce & Co., Inc. | 402,105 | $10,724,000 | 2.28% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 297,500 | $7,934,000 | 1.91% |
| ARMISTICE CAPITAL, LLC | 3,900,000 | $104,013,000 | 1.76% |
| Bridge City Capital, LLC | 108,884 | $2,904,000 | 1.32% |
| S&T BANK/PA | 316,098 | $8,430,000 | 1.31% |
| Kent Lake Capital LLC | 100,000 | $2,667,000 | 1.15% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 331,140 | $8,832,000 | 1.02% |
| Prairiewood Capital, LLC | 45,297 | $1,208,000 | 0.99% |